Summary:
An open-label 52-week study to assess the long-term safety of nktr-118 in opioid-induced constipation (oic) in patients with non-cancer-related pain.
The study duration will be 54 to 58 weeks. The study will consist of 52 weeks of open-label treatment followed by a 2 week follow-up period.
Qualified Participants Must:
• Have constipation (less than or equal to 3 bowel movements per week) due to use of opiod pain medications (30 mg daily for at least 4 weeks)
•
Be 18-85 years of age
•
Not be taking opiod pain medications for cancer pain
•
Meet other qualification that apply
Qualified Participants May Receive:
Study medical examinations, laboratory evaluations, study medication, time and travel compensation ofr completed study visits.